|
Mar 9
|
Wave Life Sciences Ltd. (NASDAQ:WVE) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
|
|
Mar 8
|
We Think Wave Life Sciences (NASDAQ:WVE) Can Easily Afford To Drive Business Growth
|
|
Mar 8
|
Wave Life Sciences Full Year 2023 Earnings: Beats Expectations
|
|
Mar 7
|
Wave Life Sciences Ltd. (NASDAQ:WVE) Q4 2023 Earnings Call Transcript
|
|
Mar 6
|
Wave Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
|
|
Feb 28
|
Wave Life Sciences Fourth Quarter and Full Year 2023 Financial Results Scheduled for March 6, 2024
|
|
Feb 28
|
Wave Life Sciences (WVE) Surges 10.9%: Is This an Indication of Further Gains?
|
|
Feb 27
|
Wave Life Sciences Announces Upcoming Presentations at MDA Conference that Highlight Best-in-Class Potential for WVE-N531 in Duchenne Muscular Dystrophy
|
|
Dec 15
|
Wave Life Sciences Announces Initiation of Dosing in Phase 2 FORWARD-53 Trial of WVE-N531 in Duchenne Muscular Dystrophy
|
|
Dec 13
|
Wave Life Sciences Ltd.'s (NASDAQ:WVE) recent 35% pullback adds to one-year year losses, institutional owners may take drastic measures
|
|
Dec 7
|
Wave Life Sciences Prices $100 Million Public Offering of Ordinary Shares
|
|
Dec 6
|
Wave Life Sciences Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants
|
|
Dec 6
|
Wave Life Sciences Announces Initiation of Dosing in RestorAATion Clinical Program Evaluating First-Ever RNA Editing Candidate, WVE-006, for Alpha-1 Antitrypsin Deficiency
|
|
Sep 6
|
Wave Life Sciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference
|
|
Sep 5
|
Wave Life Sciences Announces Submission of First Clinical Trial Application for WVE-006, the First-ever RNA Editing Clinical Candidate, and Plans for Upcoming Virtual “R&D Day”
|
|
Jul 6
|
Wave Life Sciences (NASDAQ:WVE) shareholders have endured a 90% loss from investing in the stock five years ago
|
|
Apr 26
|
Wave Life Sciences First Quarter 2023 Financial Results Scheduled for May 3, 2023
|